FINDINGS RELEASED FROM NAXOS, A FRENCH REAL-WORLD DATA ANALYSIS AND THE LARGEST REAL-WORLD DATA ANALYSIS ON ORAL ANTICOAGULANT EFFECTIVENESS AND SAFETY IN EUROPE AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
Eliquis® (apixaban) was associated with a lower rate of major bleeding, stroke and systemic thromboembolic events compared to a vitamin K antagonist. Results show Eliquis was associated with a lower rate of major bleeding and comparable rates of stroke and systemic thromboembolic events versus dabig...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
InterMedservice
2019-12-01
|
| Series: | Евразийский Кардиологический Журнал |
| Online Access: | https://www.heartj.asia/jour/article/view/353 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Eliquis® (apixaban) was associated with a lower rate of major bleeding, stroke and systemic thromboembolic events compared to a vitamin K antagonist. Results show Eliquis was associated with a lower rate of major bleeding and comparable rates of stroke and systemic thromboembolic events versus dabigatran or rivaroxaban. This late-breaking presentation is one of 11 Bristol-Myers Squibb-Pfizer Alliance abstracts being presented at the European Society of Cardiology Congress 2019. |
|---|---|
| ISSN: | 2225-1685 2305-0748 |